Dabrafenib Plus Trametinib Better Preserve Quality of Life vs. Dabrafenib Alone

Share this content:
Combination of dabrafenib and trametinib provides better preservation of health-related quality of life and pain improvements.
Combination of dabrafenib and trametinib provides better preservation of health-related quality of life and pain improvements.

The combination of dabrafenib and trametinib provides better preservation of health-related quality of life (HRQoL) and pain improvements compared with dabrafenib monotherapy while also delaying disease progression, a recent study published in the European Journal of Cancer has shown.

For the study, researchers sought to analyze the impact of treatments on HRQoL from the COMBI-d study that evaluated the combination of dabrafenib and trametinib versus dabrafenib alone in patients with BRAF V600/K-mutant metastatic melanoma.

Results showed that global health dimension scores were significantly better at weeks 8, 16, and 24 for those receiving dabrafenib plus trametinib during treatment and at progression.

Researchers also found that the majority of functional dimension scores trended in favor of the combination regimen.

RELATED: Personalized Vaccine for Advanced Melanoma Shows Promise

The study also showed that pain scores were significantly improved and clinically meaningful for patients receiving dabrafenib and trametinib for all follow-up assessments compared with those receiving dabrafenib alone.

However, for other symptom dimensions, scored trended in favor of the monotherapy.

Reference

  1. Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in ra randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015. [Epub ahead of print]. doi: 10.1016/j.ejca.2015.03.004.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs